Pearls from the EGS Guidelines

This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.

COOKIE NOTICE

Our site uses cookies. You can find more information about cookies, how we use them and how to control them in the sections below. By using this website you accept the use of cookies under this Cookie Notice. If the user doesn’t like to make use of cookies he should deactivate them by following the instructions in this notice so that the cookie from this site can not be saved on the device from which you surf.

What is a cookie?

Cookies are small text files that are sent to the PC or to the device used when visiting a website. Cookies are then sent back to the site that created them at each subsequent visit, or to another website that recognizes the same cookie. Cookies act as a memory space for a website, allowing the site to remember a specific device during subsequent accesses after the first. Cookies can also store preferences, user experience, as well as customize the advertising displayed. You can find more information about cookies and how to view, manage and delete cookies on your device by accessing the website www.aboutcookies.org.

Types of cookies

Session and persistent cookies

The site can make use of session cookies that remain on your device until you close the browser or persistent cookies that last for a longer period of time.

Intents

The cookies of our website are used for one or more of the following aims:

Strictly necessary

Cookies that are strictly necessary to provide you with the requested service.

Performance

Cookies that collect information about user behavior on the site. For instance which pages visitors visit more often and if error messages are transmitted from web pages.

Functionality
Cookies that enable the website to remember choices that the user performs (such as a user name, language or region) by providing services and features calibrated on the user’s profile.

Targeting or advertising
We use cookies to show advertising messages more relevant to each user according to individual interests. They are also used to limit the number of times a user sees a specific advertising and to measure the effectiveness of an advertising campaign.

Third-party cookies

Our website can allow generation of cookies by third-party services that appear on the site. These cookies are not under our control. For more information about specific third-party cookies, please visit their websites.

How to control and delete cookies

Most browsers accept cookies, but you can usually modify your browser setting to refuse new cookies, disable existing ones or simply know when they are sent to the device. In order to set your browser to refuse cookies, refer to the instructions on “help” provided by the supplier of the browser (usually this option is found in the menu “Help”, “Tools” or “Modify”) . More information is available on website www.aboutcookies.org.
In the event that you refuse or disable cookies, some of the features of this website may not work properly. Moreover, the deactivation of a cookie or a cookie category does not delete the cookie from the browser. To proceed with the elimination it will be necessary for the user to use special instruments within his browser, independently.

Changes to cookies

Any changes that we make to use of cookies on this site will be listed on this public page and, if necessary, reported directly on the pages of the web site, highlighted.

Contact Information

If you have any questions in relation to this notice, please contact us at info@eugs.org

Pearls from the EGS Guidelines

Glaucoma due to corticosteroids

Publishing date: June 2019

Pearls Manager: Andrew Tatham

Topical, intravitreal or systemic corticosteroids can induce acute or chronic intraocular pressure elevation. Risk factors for corticosteroid-induced IOP elevation include: primary open angle glaucoma, family history of glaucoma, diabetes, myopia, rheumatoid arthritis, children and elderly patients.
Corticosteroids induce changes in the trabecular extracellular matrix which lead to decreased outflow facility. Elevated IOP usually develops 2 to 6 weeks after initiating therapy but may occur at any time.

EGS Guidelines, 4th edition, Page 97.

Reference: Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update on the literature. Curr Opin Ophthalmol 2006;17(2):163-7.